John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE

Publication: <2014- > : Oxford : Wiley
Original Publication: Oxford ; New York : Rapid Communications, [1994-

JC Virus*; Immunologic Factors/*adverse effects ; Leukoencephalopathy, Progressive Multifocal/*complications ; Leukoencephalopathy, Progressive Multifocal/*epidemiology ; Multiple Sclerosis/*complications ; Multiple Sclerosis/*epidemiology ; Natalizumab/*adverse effects; Adult ; Antibodies, Viral/blood ; Cohort Studies ; Female ; Humans ; Immunologic Factors/blood ; Immunologic Factors/therapeutic use ; Male ; Middle Aged ; Natalizumab/blood ; Natalizumab/therapeutic use ; Prospective Studies ; Risk

Background and Purpose: Infection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause.
Methods: Natalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients.
Results: One hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index.
Conclusions: Higher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients.
(© 2017 EAN.)

Keywords: JC virus; multiple sclerosis; natalizumab

0 (Antibodies, Viral)
0 (Immunologic Factors)
0 (Natalizumab)

Date Created: 20170715 Date Completed: 20180323 Latest Revision: 20181202

20231215

10.1111/ene.13355

28707781